Minton M J, Knight R K, Rubens R D, Hayward J L
Cancer. 1981 Aug 15;48(4):883-7. doi: 10.1002/1097-0142(19810815)48:4<883::aid-cncr2820480404>3.0.co;2-v.
Ninety-one assessable elderly women (greater than 65 years) with advanced breast cancer were treated with prednisolone 15 mg (or cortisone 75 mg) daily after primary endocrine treatment (estrogens, androgens or tamoxifen). Thirteen (14%) achieved an objective regression, and 19 (21%) others showed no change for greater than or equal to six months. Hence, 32 patients (35%) had control of disease for about one year. Responses were mainly in soft tissue and skeletal lesions and were independent of response to prior endocrine treatment. Toxicity was low. Low-dose corticosteroid treatment is of value in controlling advanced breast cancer in elderly women.
91例可评估的老年女性(年龄大于65岁)晚期乳腺癌患者在接受初始内分泌治疗(雌激素、雄激素或他莫昔芬)后,每日服用15mg泼尼松龙(或75mg可的松)。13例(14%)实现了客观缓解,另有19例(21%)在大于或等于6个月的时间内病情无变化。因此,32例患者(35%)病情得到了约一年的控制。缓解主要出现在软组织和骨骼病变中,且与先前内分泌治疗的反应无关。毒性较低。低剂量皮质类固醇治疗对于控制老年女性晚期乳腺癌具有价值。